Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by StockNews.com

StockNews.com started coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI) in a report issued on Sunday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Other equities research analysts have also recently issued reports about the stock. Needham & Company LLC reaffirmed a “hold” rating and set a $100.00 price objective on shares of Intra-Cellular Therapies in a research report on Monday, January 13th. JPMorgan Chase & Co. upped their price objective on Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an “overweight” rating in a research report on Monday, November 4th. Cantor Fitzgerald raised Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 14th. Baird R W downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Finally, Piper Sandler restated a “neutral” rating and set a $132.00 price objective (up previously from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Nine analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Intra-Cellular Therapies presently has an average rating of “Moderate Buy” and an average target price of $103.62.

Intra-Cellular Therapies Trading Up 0.1 %

NASDAQ:ITCI opened at $127.96 on Friday. The stock has a fifty day moving average price of $106.66 and a 200 day moving average price of $88.38. Intra-Cellular Therapies has a 12-month low of $62.78 and a 12-month high of $128.19. The firm has a market cap of $13.60 billion, a PE ratio of -147.08 and a beta of 0.72.

Insider Buying and Selling

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 51,000 shares of the stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the completion of the sale, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at approximately $91,834,228.20. This trade represents a 4.55 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Norges Bank purchased a new position in Intra-Cellular Therapies in the 4th quarter valued at $268,347,000. Raymond James Financial Inc. acquired a new stake in shares of Intra-Cellular Therapies in the 4th quarter worth $76,451,000. Adage Capital Partners GP L.L.C. lifted its stake in shares of Intra-Cellular Therapies by 266.5% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 678,000 shares of the biopharmaceutical company’s stock worth $56,627,000 after acquiring an additional 493,000 shares during the period. TimesSquare Capital Management LLC boosted its holdings in shares of Intra-Cellular Therapies by 91.8% in the fourth quarter. TimesSquare Capital Management LLC now owns 840,269 shares of the biopharmaceutical company’s stock valued at $70,179,000 after acquiring an additional 402,186 shares in the last quarter. Finally, Deep Track Capital LP increased its stake in shares of Intra-Cellular Therapies by 24.9% during the fourth quarter. Deep Track Capital LP now owns 2,000,000 shares of the biopharmaceutical company’s stock worth $167,040,000 after acquiring an additional 399,307 shares during the period. Institutional investors and hedge funds own 92.33% of the company’s stock.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.